Drug
CER-001
CER-001 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
4
80%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3
Trials by Phase
Phase 24 (80.0%)
Phase 31 (20.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_3
CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
NCT02697136
completedphase_2
CER-001 Atherosclerosis Regression ACS Trial
NCT02484378
completedphase_2
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
NCT01412034
completedphase_2
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
NCT01201837
completedphase_2
Exploratory Study of Plaque Regression
NCT01515241
Clinical Trials (5)
Showing 5 of 5 trials
NCT02697136Phase 3
CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
NCT02484378Phase 2
CER-001 Atherosclerosis Regression ACS Trial
NCT01412034Phase 2
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
NCT01201837Phase 2
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
NCT01515241Phase 2
Exploratory Study of Plaque Regression
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5